Gene therapy for sickle cell disease passes key preclinical test

$ 4.50

4.7
(382)
In stock
Description

A precision-engineered gene therapy virus, inserted into blood stem cells that are then transplanted, markedly reduced sickle-induced red-cell damage in mice with sickle cell disease, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported in the Journal of Clinical Investigation.

Денис Савин (@withoutpassions) / X

Sickle cell gene therapy passes key preclinical test - Boston Children's Answers

News & Events - latest news and happenings in the SCD community

Sickle cell gene therapy passes key preclinical test - Boston Children's Answers

Dr.mrs jugesh saluja (@jugeshsaluja) / X

Archives — Page 198 of 873 — Harvard Gazette

Editor's Pick Archives — Page 33 of 225 — Harvard Gazette

Researchers optimize gene editing for SCD and beta thalassemia

Dr.mrs jugesh saluja (@jugeshsaluja) / X